These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16840200)

  • 21. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
    Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R
    Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
    Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.
    Goh HG; Kim YJ; Kim DW; Kim HJ; Kim SH; Jang SE; Lee J; Kim D; Kim WS; Park SH; Kweon IY
    Leuk Lymphoma; 2009 Jun; 50(6):944-51. PubMed ID: 19479613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
    J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
    Kantarjian HM; Cortes JE; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Jeha S; Rios MB; Letvak L; Bochinski K; Arlinghaus R; Talpaz M
    Blood; 2003 Jan; 101(1):97-100. PubMed ID: 12393600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
    Takahashi N; Miura I; Kobayashi Y; Kume M; Yoshioka T; Otane W; Ohtsubo K; Takahashi K; Kitabayashi A; Kawabata Y; Hirokawa M; Nishijima H; Ichinohasama R; Decoteau J; Miura AB; Sawada K
    Int J Hematol; 2005 Apr; 81(3):235-41. PubMed ID: 15814334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
    Chrobák L; Voglová J
    Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
    Palamà IE; Coluccia AM; Gigli G
    Nanomedicine (Lond); 2014 Jul; 9(14):2087-98. PubMed ID: 24364873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
    Jabbour E; Kantarjian HM; Jones D; Shan J; O'Brien S; Reddy N; Wierda WG; Faderl S; Garcia-Manero G; Verstovsek S; Rios MB; Cortes J
    Blood; 2009 Mar; 113(10):2154-60. PubMed ID: 19060245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experimental advance of targeted medicines for chronic myeloid leukemia--review].
    Yang DG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):211-4. PubMed ID: 17490557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.